Quintiles has acquired Expression Analysis, Inc. (EA), a provider of genomics testing and analysis to biopharma, academic, government and non-profit customers. Terms of the transaction were not disclosed.
 
EA provides whole genome to focused-set gene expression and genotyping assays, along with next-generation sequencing services, sequence enrichment technologies and bioinformatics support. It offers a broad range of services across multiple platforms. EA has 77 employees, most of which are based in offices near Research Triangle Park, NC.
 
“The addition of EA’s Genomic Know-How to Quintiles is another step forward in our efforts to bring personalized medicine into mainstream drug development,” said Thomas Wollman, senior vice president, Quintiles Global Laboratories. “Its expertise in genetic sequencing and advanced bioinformatics is essential to understanding diseases and drugs at the molecular level. That’s a huge step in creating more value across the healthcare spectrum.”
 
Steve McPhail, EA president and chief executive officer, said, “The combination of Quintiles Global Laboratories and EA genomic technology excellence will facilitate worldwide access to resources and expertise to drive improvements in the diagnosis, treatment and management of complex disease. EA can now play a global role in helping biopharma succeed in the New Health.